Drugs / Cannabinol
Cannabinol
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT05344170 | Aug 2022 → Aug 2023 | insomnia | Woolcock Institute of Medical Research | Completed | Missed primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT04908215 | Dec 2021 → Apr 2023 | Kindler syndrome, epidermolysis bullosa dystrophica, epidermolysis bullosa simplex, junctional epidermolysis bullosa | InMed Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03675971 | May 2020 → May 2021 | osteoarthritis, knee | Unity Health Toronto | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2024-11-19 | InMed Pharmaceuticals Inc. | Results InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System inmedpharma.com ↗
This Company-sponsored study demonstrates the biological activity of cannabinol (“CBN”) and its potential anti-inflammatory effects in skin diseases. |
| 2023-11-29 | InMed Pharmaceuticals Inc. | Results InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration inmedpharma.com ↗
Results from a study, conducted under a collaborative research agreement with leading cannabinoid expert Dr. Mauro Maccarrone at the Università degli Studi dell’Aquila (Italy), demonstrated that INM-089 preserved retinal function in an in vivo AMD disease model. |
| 2023-11-02 | InMed Pharmaceuticals Inc. | Results InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 inmedpharma.com ↗
The data showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone. |
| 2023-06-22 | InMed Pharmaceuticals Inc. | Results InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa inmedpharma.com ↗ |
| 2021-12-20 | InMed Pharmaceuticals Inc. | Results InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma inmedpharma.com ↗
These studies resulted in two key findings: first, CBN may promote neuroprotection of cells in the retina that are responsible for vision; and second, CBN may normalize intraocular pressure by attenuating changes in the extracellular matrix proteins. |
| 2021-04-28 | InMed Pharmaceuticals Inc. | Regulatory InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa inmedpharma.com ↗ |
| 2021-01-08 | InMed Pharmaceuticals Inc. | Results InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects inmedpharma.com ↗
Results of Study 102 indicate that INM-755 cream was safe and well-tolerated on induced open epidermal wounds, caused no systemic or serious adverse effects, and there were no subject withdrawals due to adverse events. |
| 2020-11-25 | InMed Pharmaceuticals Inc. | Results InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects inmedpharma.com ↗
Results of Study 101 indicate that INM-755 was safe and well-tolerated on intact skin, caused no systemic or serious adverse effects, and there were no subject withdrawals due to adverse events. |
| 2020-05-27 | InMed Pharmaceuticals Inc. | Results InMed Releases CBN Preclinical Results in Glaucoma inmedpharma.com ↗
However, the combination of CBN and elevated pressure, within the same time period, resulted in a high level of cell survival in a dose dependent fashion. |
| 2020-04-30 | InMed Pharmaceuticals Inc. | Regulatory InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755 inmedpharma.com ↗
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced it has received regulatory and ethics board approval of its Clinical Trial Application (“CTA”) to conduct its second Phase 1 trial with INM-755. |
| 2020-03-24 | InMed Pharmaceuticals Inc. | Regulatory InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial inmedpharma.com ↗ |
| 2019-12-09 | InMed Pharmaceuticals Inc. | Regulatory InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa inmedpharma.com ↗ |
| 2019-11-05 | InMed Pharmaceuticals Inc. | Regulatory InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial inmedpharma.com ↗
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. |
All press releases naming this drug 23 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cannabinol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03675971 ↗ |
| Known as | CBN | “This study aims to investigate the acute effects of cannabinol (CBN) 30 mg and 300 mg, versus placebo, on sleep architecture and next-day functioning in adults aged 25-65 years...” NCT05344170 ↗ |
| Known as | INM-755 | “The purpose of this study is to evaluate the safety of INM-755 (cannabinol) cream and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a...” NCT04908215 ↗ |
| Known as | NSC-134455 | ChEMBL registry synonym — accepted as the source's own label CHEMBL74415 ↗ |
| Modality | Small molecule | — CHEMBL74415 ↗ |
| Route | Topical | “Cannabinol cream, topically applied daily in thin layer on non-wound index areas and every 1, 2 or 3 days in thick layer on dressings for index wounds for a 28-day period.” NCT04908215 ↗ |